含萘丙氨酸与碘代苯丙氨酸的脲基PSMA抑制剂合成及体内外评价
本研究合成并评价了9种脲基PSMA抑制剂,其中引入萘丙氨酸的化合物5和6亲和力最高,较参照物PSMA I&T高至3倍;DOTAGA偶联的68Ga-10在LNCaP荷瘤小鼠中实现有效肿瘤靶向,而引入4-碘-D-苯丙氨酸的177Lu-11血浆蛋白结合率达97%,24小时肿瘤摄取16.1±2.5%ID/g,较177Lu-PSMA I&T提高近4倍,但肾脏高摄取仍是缺陷,需进一步研究其机制。
要点
- 萘丙氨酸修饰使化合物5和6的PSMA亲和力较PSMA I&T提高至3倍。
- 68Ga-10血浆蛋白结合率80%,在LNCaP荷瘤小鼠1小时实现有效肿瘤靶向。
- 177Lu-11血浆蛋白结合率97%,24小时肿瘤摄取16.1±2.5%ID/g,较177Lu-PSMA I&T提高近4倍。
核心结论
- 新型PSMA配体10和11的高脂溶性有利于亲和力和内化,并较母体化合物获得更高的肿瘤摄取。
- 在配体11的连接臂中引入对碘苯丙氨酸提高了血浆蛋白结合率,使肿瘤蓄积持续超过24小时,肿瘤摄取较177Lu-PSMA I&T提高近4倍。
- 肾脏高摄取仍是缺陷,需进一步研究以阐明其机制。
研究设计与样本
- 本研究合成化合物1-9并进行体外评价,另对DOTAGA偶联的10及引入4-碘-D-苯丙氨酸的11进行体内评价。
- 体内评价采用LNCaP荷瘤CD-1 nu/nu小鼠,行小动物PET显像与生物分布研究。
主要发现
- 化合物5和6引入萘丙氨酸修饰后PSMA亲和力最高(IC50最低),亲和力较参照物PSMA I&T高至3倍。
- 化合物4中联苯丙氨酸等延伸芳香体系损害了与PSMA亲脂性结合口袋的相互作用,亲和力降低10倍。
- DOTAGA偶联的10的IC50较其乙酰化类似物略升高;68Ga-10血浆蛋白结合率80%,在LNCaP荷瘤CD-1 nu/nu小鼠1小时实现有效肿瘤靶向且非靶组织摄取低。
- 177Lu-11在24小时的肿瘤摄取为16.1±2.5%ID/g,血浆蛋白结合率97%。
关键数值与推荐
- 化合物5和6的PSMA亲和力较参照物PSMA I&T高至3倍。
- 化合物4的亲和力较参照物降低10倍。
- 68Ga-10血浆蛋白结合率80%。
- 177Lu-11血浆蛋白结合率97%,24小时肿瘤摄取16.1±2.5%ID/g,较177Lu-PSMA I&T提高近4倍。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 肾脏高摄取仍是缺陷,需进一步研究以阐明其机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several radiolabeled prostate-specific membrane antigen (PSMA) inhibitors based on the lysine-urea-glutamate (KuE) motif as the pharmacophore proved to be suitable tools for PET/SPECT imaging of the PSMA expression in prostate cancer patients. PSMA I&T, a theranostic tracer developed in our group, was optimized through alteration of the peptidic structure in order to increase the affinity to PSMA and internalization in PSMA-expressing tumor cells. However, further structural modifications held promise to improve the pharmacokinetic profile. RESULTS: Among the investigated compounds 1-9, the PSMA inhibitors 5 and 6 showed the highest PSMA affinity (lowest IC50 values) after the introduction of a naphthylalanine modification. The affinity was up to three times higher compared to the reference PSMA I&T. Extended aromatic systems such as the biphenylalanine residue in 4 impaired the interaction with the lipophilic binding pocket of PSMA, resulting in a tenfold lower affinity. The IC50 of DOTAGA-conjugated 10 was slightly increased compared to the acetylated analog; however, efficient PSMA-mediated internalization and 80% plasma protein binding of 68Ga-10 resulted in effective tumor targeting and low uptake in non-target tissues of LNCaP tumor-bearing CD-1 nu/nu mice at 1 h p.i., as determined by small-animal PET imaging and biodistribution studies. For prolonged tumor retention, the plasma protein binding was increased by insertion of 4-iodo-D-phenylalanine resulting in 97% plasma protein binding and 16.1 ± 2.5% ID/g tumor uptake of 177Lu-11 at 24 h p.i. CONCLUSIONS: Higher lipophilicity of the novel PSMA ligands 10 and 11 proved to be beneficial in terms of affinity and internalization and resulted in higher tumor uptake compared to the parent compound. Additional combination with para-iodo-phenylalanine in the spacer of ligand 11 elevated the plasma protein binding and enabled sustained tumor accumulation over 24 h, increasing the tumor uptake almost fourfold compared to 177Lu-PSMA I&T. However, high renal uptake remains a drawback and further studies are necessary to elucidate the responsible mechanism behind it.
引用
- Wirtz M, Schmidt A, Schottelius M, et al. Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity. EJNMMI Res. 2018. PMID: 30136051. doi:10.1186/s13550-018-0440-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。